Table 2.
Chemical agents representing therapeutic strategies for EBOV infection.
| Compound | Viral target |
|---|---|
| Neplanocin A | SAH hydrolase |
| 3-Deazaneplanocin A | SAH hydrolase |
| BCX4430 | RNA polymerase |
| Favipiravir (T-705) | RNA polymerase |
| Lectins | Viral entry |
| Glucosidase inhibitors | Viral entry |
| FGI compounds | Unknown |
| Antioxidant NSC62914 | Reactive oxygen species (ROS) |
| Benzylpiperazine adamantane diamides | Viral entry |
| LJ-001 | Viral entry |
| dUY11 | Viral entry |
| SERMS (clomiphene, toremifene) | Viral entry |
| Ion channel blockers | Viral entry |
| CMLDBU3402 | RNA polymerase |
| HSPA5 inhibitors | Unknown |
| Heme oxygenase-1 (HO-1) | Unknown |
| Miscellaneous inhibitors of cathepsin L cleavage | Viral entry |
| Chloroquine | Unknown |